Rhythm Pharmaceuticals (NASDAQ:RYTM) vs. Senti Biosciences (NASDAQ:SNTI) Head to Head Contrast

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) and Senti Biosciences (NASDAQ:SNTI – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

25.7% of Senti Biosciences shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Rhythm Pharmaceuticals has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500.

Profitability

This table compares Rhythm Pharmaceuticals and Senti Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals -69.03% -171.16% -43.00%
Senti Biosciences N/A -1,629.80% -119.72%

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and Senti Biosciences”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rhythm Pharmaceuticals $189.76 million 42.02 -$196.54 million ($2.90) -39.66
Senti Biosciences $20,000.00 218.05 -$61.44 million ($1.77) -0.08

Senti Biosciences has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rhythm Pharmaceuticals and Senti Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals 1 3 18 0 2.77
Senti Biosciences 1 0 1 1 2.67

Rhythm Pharmaceuticals presently has a consensus price target of $142.00, suggesting a potential upside of 23.46%. Senti Biosciences has a consensus price target of $9.00, suggesting a potential upside of 6,328.57%. Given Senti Biosciences’ higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Rhythm Pharmaceuticals.

Summary

Senti Biosciences beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Rhythm Pharmaceuticals

(Get Free Report)

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.

About Senti Biosciences

(Get Free Report)

Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.